Clinical trials
Autoantibodies clinical trials
Below are recruiting autoantibodies clinical trials, each written for real people, not researchers. We’re tracking 29 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07316465Recruiting
Tracking immune markers in newborns at risk for eczema
This study follows newborns for two years to see how their immune system develops, especially if they have a family history of eczema, asthma, or hay fever. Researchers want to learn if certain immune markers appear early in babies who later develop eczema.
Jette, Brussels CapitalAges 1 hour–2 years - NCT06594861Recruiting
Follow-up study for Ro/SSA and La/SSB antibodies
This study follows people who have tested positive for Ro/SSA or La/SSB antibodies (proteins linked to certain autoimmune conditions). It also includes a control group of people without these antibodies or any rheumatologic disease. The goal is to learn more about long-term health patterns.
StockholmAges 18 years+ - NCT07726563Recruiting
Plasmapheresis for ALS with NRIP2 antibody
This trial tests whether a blood filtering treatment called plasmapheresis can help people with ALS who have a specific antibody (NRIP2) in their blood. It aims to see if removing this antibody can slow the disease and improve symptoms.
Taipei City, TaipeiAges 20 years+ - NCT04993885RecruitingPhase 2
Avatrombopag for adults with immune low platelets
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06941584Recruiting
AIRE gene's role in autoimmune nerve diseases
This study looks at how the AIRE gene affects people with autoimmune nerve diseases like NMOSD, myasthenia gravis, and autoimmune encephalitis when they also have other autoimmune conditions. It may help researchers understand why some people get multiple autoimmune problems.
RomaAges 18 years+ - NCT06665815Recruiting
Screening close family for type 1 diabetes risk
This study screens close family members of people with type 1 diabetes for early signs of the condition. A simple blood test looks for special markers (autoantibodies) that can show if the immune system is starting to attack the pancreas. Finding these markers early may help doctors prevent or delay the onset of diabetes.
Petah TikvaAges 2–45 - NCT06943365Recruiting
Role of Anti-TREK-1 Antibodies in Sudden Cardiac Arrest Without Blockage
This study looks for a specific type of antibody (called anti-TREK-1) in the blood of people who have had a sudden cardiac arrest without a clear cause. It aims to understand if these antibodies play a role in the condition, which might help with future diagnosis or treatment.
Vancouver, British ColumbiaAges 18 years+ - NCT06141434Recruiting
Maternal Exposures and Baby Diabetes Risk Study
This study follows pregnant women and their babies to learn how early-life factors may affect the risk of type 1 diabetes. If your baby has a parent or sibling with type 1 diabetes, you may be able to join.
Aurora, ColoradoAges birth–99 years - NCT06317467Recruiting
Anti-C1q antibodies and pregnancy outcomes study
This study looks at a specific antibody (anti-C1q) in pregnant women, including those with normal pregnancies, preeclampsia (high blood pressure and protein in urine after 20 weeks), or autoimmune conditions like lupus or antiphospholipid syndrome. The goal is to understand how this antibody might affect pregnancy and help guide care.
TriesteAges 18 years+ - NCT06513247Recruiting
Screening for type 1 diabetes in high-risk relatives
This study screens high-risk children for early signs of type 1 diabetes by testing relatives who already have the condition. It aims to catch diabetes early so treatment can start sooner.
RiyadhAges 2–18 - NCT04834518Recruiting
Screening children for early signs of type 1 diabetes
This study checks for specific blood markers (“islet autoantibodies”) to find children who may be at risk for developing type 1 diabetes later, before symptoms start. It’s mainly for children who have no known diabetes yet.
BeershebaAges 9 months–5 years - NCT07529197Recruiting
Study of Immunoadsorption Treatment for Post-Infectious ME/CFS
This study observes how a blood-cleaning treatment called immunoadsorption works in patients with ME/CFS (severe fatigue condition) who have specific immune markers. Researchers will track whether this treatment helps reduce symptoms and improve daily functioning.
Berlin, State of BerlinAges 18–65 - NCT06761209Recruiting
Autoantibody negativity and autoimmune hepatitis severity
This trial checks if the absence of certain antibodies in autoimmune hepatitis (AIH) is linked to more severe disease. It may help doctors better understand and treat AIH.
Paris, FranceAges 18 years+ - NCT07477015Recruiting
Study to find new antibodies in autoimmune encephalitis
This research study looks for new markers in the blood of people with autoimmune encephalitis (a condition where the immune system attacks the brain). It aims to better understand what causes the disease and find new ways to diagnose it.
Rome, RMAges 18 years+ - NCT07441525RecruitingEarly Phase 1
CAR-T cell therapy for hard-to-treat autoimmune blood diseases
This early-stage trial tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and BCMA, in people with autoimmune blood diseases like ITP, AIHA, or Evans syndrome that have not responded to standard treatments. It aims to reset the immune system and reduce production of harmful antibodies.
Wuhan, HubeiAges 18–75 - NCT07391605RecruitingPhase 2
Descartes-08 for treatment-resistant myositis
This trial tests a new treatment called Descartes-08 for people with dermatomyositis or antisynthetase syndrome whose disease hasn't responded well to standard therapies. It aims to see if this treatment can help control muscle and skin symptoms.
Orange, CaliforniaAges 18 years+ - NCT07125365Recruiting
UK study tracking islet antibodies in children and adults
This study enrolls people with islet autoantibodies, which are early markers for type 1 diabetes. It aims to understand who develops these antibodies and how they are linked to diabetes over time. No treatment is given—you just provide blood samples and answer questions.
Oxford, OxfordshireAges 6 months–70 years - NCT07103746RecruitingPhase 2
Ublituximab for antibody-positive IMNM
This study tests an investigational medication called ublituximab (an infusion) for people with a rare autoimmune muscle disease called IMNM. It aims to reduce muscle weakness and damage by targeting specific immune cells (B cells). To join, you need a recent diagnosis (within 1 year), specific antibodies, and be on limited other medications.
Birmingham, AlabamaAges 18 years+ - NCT07093333RecruitingPhase 2
Testing a new antibody treatment for anti-NMDAR brain disease
This study tests a new medicine (ART5803) in people whose immune system attacks a brain receptor called NMDAR, causing encephalitis (brain swelling) or psychiatric symptoms. It aims to see if the medicine can reduce symptoms like confusion, memory problems, or psychosis.
SeoulAges 18–65 - NCT06869590Recruiting
Study of antibodies in anorexia with liver damage
This study looks for certain antibodies in the blood of people with anorexia nervosa who also have liver problems. It aims to understand if these antibodies contribute to liver damage, which may help find new ways to treat or prevent this complication.
MarseilleAges 6–65 - NCT06762002Recruiting
Immune system study for people with certain immune weaknesses
This study is for adults whose immune system has trouble fighting viruses due to specific antibodies or a genetic condition. Researchers want to follow these people over time to better understand the condition and improve care.
LilleAges 18 years+ - NCT06388161Recruiting
Autoantibody study in new focal seizures
This research study looks for specific immune system markers (autoantibodies) in the blood and spinal fluid of people who have recently started having focal seizures (seizures that start in one part of the brain) with no known cause. Finding these markers could help doctors understand why the seizures started.
Hangzhou, ZhejiangAges 14–100 - NCT06334692Recruiting
Autoantibody study in nephrotic syndrome
This study looks for specific proteins (autoantibodies) in your blood that may be linked to certain kidney diseases. It aims to better understand the immune system's role in minimal change disease and FSGS, which could lead to better treatments.
Ranica, BGAges 18 years+ - NCT06427421Recruiting
Immune cells in children with recent type 1 diabetes
This study looks at immune cells in children who were recently diagnosed with type 1 diabetes. It involves one extra blood draw to better understand how the immune system attacks the pancreas. If you join, no new treatments are given—just observation and analysis of your child's immune cells.
ParisAges 6–18
Hear when a new Autoantibodies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autoantibodies?
- Yes. Clin2 currently lists 29 recruiting autoantibodies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autoantibodies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autoantibodies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.